ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
mRNA 치료제 CDMO 시장 규모는 향후 수년간 급성장이 전망됩니다. 2029년에는 CAGR 11.8%로 74억 달러로 성장합니다. 이 예측 기간의 성장 배경에는 맞춤형 의료에 대한 관심 증가, 신흥 질환에 대한 신속한 대응 플랫폼에 대한 수요 증가, 개발도상국의 의료비 지출 증가, 국내 제조에 대한 정부 인센티브 증가, 비감염성 질환에 대한 mRNA 기술 적용에 대한 관심 증가 등이 있습니다. 이 기간의 주요 동향으로는 지질 나노입자 전달 기술의 발전, 제조 공정의 자동화 발전, 모듈식 및 연속 생산 플랫폼의 광범위한 채택, 콜드체인 물류 인프라의 개선, 공정 최적화를 위한 인공지능의 통합 증가 등이 있습니다.
만성질환 및 감염성 질환의 부담 증가는 향후 수년간 mRNA 치료제 CDMO 시장의 성장을 가속할 것으로 예측됩니다. 만성질환 및 감염성 질환에는 당뇨병, 심혈관 질환, 천식 등 장기적인 건강 상태와 개인 간 전염되는 바이러스, 세균, 기생충 등 병원균에 의한 감염이 포함됩니다. mRNA 치료제 CDMO는 표적화된 맞춤형 mRNA 치료제의 제공을 가속화하는 종합적인 개발 및 제조 서비스를 제공함으로써 이러한 질병 퇴치를 위한 노력을 지원하고 있습니다. 예를 들어 2024년 4월 영국에 기반을 둔 국가 자선단체인 Allergy UK는 영국에서 2,100만 명 이상이 알레르기의 영향을 받고 있으며, 2022년에 가장 많이 보고된 만성질환이 되었다고 보고했습니다. 예측에 따르면 2026년까지 유럽 인구의 절반이 적어도 한 가지 이상의 알레르기를 경험하게 될 것이라고 합니다. 그 결과, 만성질환 및 감염성 질환의 부담이 증가하여 mRNA 치료제 CDMO 시장 확대에 기여하고 있습니다.
mRNA 치료제 CDMO 시장의 주요 기업은 in situ 나노의학 백신과 같은 혁신적인 개발에 집중하고 있으며, 표적 면역반응을 통해 mRNA 기반 치료의 정확성과 효능을 높이고 있습니다. in situ 나노의약품 백신은 환자의 체내에서 나노의약품의 체내 생성을 촉진하는 차세대 mRNA 치료제입니다. 이를 통해 고도로 표적화된 전달과 공학적으로 도입된 유전자 발현을 통한 맞춤형 면역 활성화가 가능합니다. 예를 들어 2025년 1월 캐나다에 본사를 둔 생명공학 기업 에스페라 심바이오(Espera Symbio)는 CQDM Quantum Leap Program의 지원을 받아 새로운 노력을 시작했습니다. 이 프로젝트는 면역 자극성 나노 의약품의 in vivo 생산을 가능하게 하는 독자적인 도입 유전자 설계를 도입하여 1세대 지질 나노입자/mRNA 백신을 개선하는 것을 목표로 하고 있습니다. 이 전략은 항원 타겟팅을 강화하고 맞춤형 면역반응을 가능하게 하여 백신 개발의 획기적인 돌파구가 될 수 있습니다.
목차
제1장 개요
제2장 시장의 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세 및 Covid와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 mRNA 치료제 CDMO : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 용도 산업의 분석
세계의 mRNA 치료제 CDMO 시장 : 성장률 분석
세계의 mRNA 치료제 CDMO 시장 실적 : 규모와 성장, 2019-2024
세계의 mRNA 치료제 CDMO 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계의 mRNA 치료제 CDMO : TAM(Total Addressable Market)
제6장 시장 세분화
세계의 mRNA 치료제 CDMO 시장 : 서비스의 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
개발 서비스
제조 서비스
실험실 서비스
세계의 mRNA 치료제 CDMO 시장 : 적응증별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
감염증
대사성 질환 및 유전성 질환
심혈관질환 및 뇌혈관 질환
세계의 mRNA 치료제 CDMO 시장 : 용도별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
바이러스 백신
단백질 보충 요법
암 면역치료
세계의 mRNA 치료제 CDMO 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제약회사
바이오테크놀러지 기업
학술기관
조사기관
세계의 mRNA 치료제 CDMO 시장 : 서브 세분화, 개발 서비스(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
프로세스 개발
분석법개발
처방 개발
규제 지원
세계의 mRNA 치료제 CDMO 시장 : 서브 세분화, 제조 서비스(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
플라스미드 DNA 제조
mRNA 합성
지질 나노입자(LNP) 제제
Fill-Finish 서비스
세계의 mRNA 치료제 CDMO 시장 : 서브 세분화, 검사 서비스(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
품질관리 테스트
안정성 시험
생체 분석 시험
전임상 시험
제7장 지역별·국가별 분석
세계의 mRNA 치료제 CDMO 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
세계의 mRNA 치료제 CDMO 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
mRNA 치료제 CDMO 시장 : 경쟁 구도
mRNA 치료제 CDMO 시장 : 기업 개요
Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
Boehringer Ingelheim Overview, Products and Services, Strategy and Financial Analysis
Danaher Corporation Overview, Products and Services, Strategy and Financial Analysis
Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 대기업과 혁신적 기업
FUJIFILM Holdings Corporation
Evonik Industries AG
BioNTech SE
AGC Biologics GmbH
Eurofins Scientific SA
Samsung Biologics Co. Ltd.
Wuxi Biologics
Recipharm AB
EMERGENT BioSolutions Inc.
Genscript Biotech
Novo Holdings AS
Ginkgo Bioworks Holdings Inc.
Corden Pharma Corp.
CureVac SE
TriLink BioTechnologies LLC
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 합병과 인수
제34장 최근 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
mRNA 치료제 CDMO 시장 2029 : 새로운 기회를 제공하는 국가
mRNA 치료제 CDMO 시장 2029 : 새로운 기회를 제공하는 부문
mRNA 치료제 CDMO 시장 2029 : 성장 전략
시장 동향에 기반한 전략
경쟁사 전략
제36장 부록
KSA
영문 목차
영문목차
An mRNA therapeutics CDMO, or messenger ribonucleic acid therapeutics contract development and manufacturing organization, is a specialized third-party provider that offers comprehensive support for the research, development, and scalable production of mRNA-based therapeutic agents under contractual agreements with pharmaceutical or biotechnology companies. These organizations are vital in accelerating time-to-market, ensuring regulatory compliance, and providing flexible manufacturing capacity for mRNA therapeutic pipelines.
The primary types of services offered by mRNA therapeutics CDMOs include development services, manufacturing services, and laboratory services. Development services encompass end-to-end support for the design, optimization, and scale-up of mRNA-based therapeutics, including synthesis, formulation, analytical development, and process development tailored to the specific needs of each client. These therapeutics are applied to treat indications such as infectious diseases, metabolic and genetic disorders, and cardiovascular and cerebrovascular conditions. Applications include viral vaccines, protein replacement therapies, and cancer immunotherapies, and the end users of these services include pharmaceutical companies, biotechnology firms, academic institutions, and research organizations.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.
The mRNA therapeutics CDMO market research report is one of a series of new reports from The Business Research Company that provides mRNA therapeutics CDMO market statistics, including mRNA therapeutics CDMO industry global market size, regional shares, competitors with a mRNA therapeutics CDMO market share, detailed mRNA therapeutics CDMO market segments, market trends and opportunities, and any further data you may need to thrive in the mRNA therapeutics CDMO industry. This mRNA therapeutics CDMO market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The mRNA therapeutics CDMO market size has grown rapidly in recent years. It will grow from $4.24 billion in 2024 to $4.74 billion in 2025 at a compound annual growth rate (CAGR) of 12.0%. The growth during the historic period can be attributed to the increasing demand for rapid vaccine development, rising public and private funding for mRNA research, a growing incidence of infectious diseases, expanding pharmaceutical outsourcing practices, and an intensified global focus on pandemic preparedness.
The mRNA therapeutics CDMO market size is expected to see rapid growth in the next few years. It will grow to $7.40 billion in 2029 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to the accelerating focus on personalized medicine, rising demand for rapid response platforms against emerging diseases, increasing healthcare expenditure in developing regions, growing government incentives for domestic manufacturing, and heightened interest in applying mRNA technologies to non-infectious diseases. Major trends during this period include advancements in lipid nanoparticle delivery technologies, increased automation in manufacturing processes, broader adoption of modular and continuous manufacturing platforms, improvements in cold chain logistics infrastructure, and the rising integration of artificial intelligence for process optimization.
The increasing burden of chronic and infectious diseases is expected to drive the growth of the mRNA therapeutics CDMO market in the coming years. Chronic and infectious diseases include long-term health conditions such as diabetes, cardiovascular diseases, and asthma, as well as infections caused by pathogens like viruses, bacteria, and parasites that can be transmitted among individuals. This rise is primarily attributed to aging populations, which are more vulnerable to both chronic illnesses and infections. mRNA therapeutics CDMOs support efforts to combat these conditions by offering comprehensive development and manufacturing services that accelerate the delivery of targeted, personalized mRNA treatments. For example, in April 2024, Allergy UK, a UK-based national charity, reported that more than 21 million people in the UK were affected by allergies, making them the most commonly reported chronic condition in 2022. Projections suggest that by 2026, half of Europe's population will experience at least one allergy. Consequently, the growing burden of chronic and infectious diseases is contributing to the expansion of the mRNA therapeutics CDMO market.
Leading companies in the mRNA therapeutics CDMO market are concentrating on innovative developments such as in situ nanomedicine vaccines to enhance the precision and effectiveness of mRNA-based treatments through targeted immune responses. An in situ nanomedicine vaccine represents a next-generation mRNA therapeutic that facilitates the internal generation of nanomedicines within the patient's body. This enables highly targeted delivery and custom immune activation through engineered transgene expression. For instance, in January 2025, Esphera SynBio Inc., a biotechnology company based in Canada, launched a new initiative backed by the CQDM Quantum Leap program. The project seeks to improve first-generation lipid nanoparticle/mRNA vaccines by introducing proprietary transgene designs that enable in vivo production of immunostimulatory nanomedicines. This strategy enhances antigen targeting and allows for customized immune responses, representing a potential breakthrough in vaccine development.
In September 2024, Agilent Technologies Inc., a US-based medical equipment company, acquired BIOVECTRA for $0.925 billion. The acquisition is intended to strengthen Agilent's CDMO capabilities in emerging therapeutic areas, particularly mRNA-based treatments, by incorporating BIOVECTRA's specialized knowledge in biologics and advanced pharmaceutical manufacturing. BIOVECTRA is a Canada-based contract development and manufacturing organization focused on mRNA therapeutics and related modalities.
Major players in the mRNA therapeutics CDMO market are Sanofi SA, Thermo Fisher Scientific Inc., Boehringer Ingelheim, Danaher Corporation, Merck KGaA, FUJIFILM Holdings Corporation, Evonik Industries AG, BioNTech SE, AGC Biologics GmbH, Eurofins Scientific SA, Samsung Biologics Co. Ltd., Wuxi Biologics, Recipharm AB, EMERGENT BioSolutions Inc., Genscript Biotech, Novo Holdings AS, Ginkgo Bioworks Holdings Inc., Corden Pharma Corp., CureVac SE, TriLink BioTechnologies LLC, Biocina Pty Ltd., Aldevron LLC, Synbio Technologies LLC, etherna manufacturing, Bio-Synthesis Inc., Biomay AG, and RiboPro.
North America was the largest region in the mRNA therapeutics CDMO market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in mRNA therapeutics CDMO report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the mRNA therapeutics CDMO market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The mRNA therapeutics CDMO market consists of revenues earned by entities by providing services such as supply chain management, cold chain logistics, quality assurance auditing, clinical trial material preparation, batch release testing, serialization, and packaging. The market value includes the value of related goods sold by the service provider or included within the service offering. The mRNA therapeutics CDMO market also includes sales of products such as lipid excipients, nucleotide reagents, capping analogs, custom RNA oligonucleotides, and modified nucleosides. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
mRNA Therapeutics CDMO Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on mrna therapeutics cdmo market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for mrna therapeutics cdmo ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The mrna therapeutics cdmo market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type Of Service: Development Services; Manufacturing Services; Laboratory Services
2) By Indication: Infectious Diseases; Metabolic And Genetic Diseases; Cardiovascular And Cerebrovascular Diseases
3) By Application: Viral Vaccines; Protein Replacement Therapies; Cancer Immunotherapies
4) By End User: Pharmaceutical Companies; Biotechnology Companies; Academic Institutions; Research Organizations
Subsegments:
1) By Development Services: Process Development; Analytical Method Development; Formulation Development; Regulatory Support
2) By Manufacturing Services: Plasmid DNA Manufacturing; mRNA Synthesis; Lipid Nanoparticle (LNP) Formulation; Fill-Finish Services
3) By Laboratory Services: Quality Control Testing; Stability Testing; Bioanalytical Testing; Preclinical Testing
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. mRNA Therapeutics CDMO Market Characteristics
3. mRNA Therapeutics CDMO Market Trends And Strategies
4. mRNA Therapeutics CDMO Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global mRNA Therapeutics CDMO Growth Analysis And Strategic Analysis Framework
5.1. Global mRNA Therapeutics CDMO PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global mRNA Therapeutics CDMO Market Growth Rate Analysis
5.4. Global mRNA Therapeutics CDMO Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global mRNA Therapeutics CDMO Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global mRNA Therapeutics CDMO Total Addressable Market (TAM)
6. mRNA Therapeutics CDMO Market Segmentation
6.1. Global mRNA Therapeutics CDMO Market, Segmentation By Type Of Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Development Services
Manufacturing Services
Laboratory Services
6.2. Global mRNA Therapeutics CDMO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Infectious Diseases
Metabolic And Genetic Diseases
Cardiovascular And Cerebrovascular Diseases
6.3. Global mRNA Therapeutics CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Viral Vaccines
Protein Replacement Therapies
Cancer Immunotherapies
6.4. Global mRNA Therapeutics CDMO Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pharmaceutical Companies
Biotechnology Companies
Academic Institutions
Research Organizations
6.5. Global mRNA Therapeutics CDMO Market, Sub-Segmentation Of Development Services, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Process Development
Analytical Method Development
Formulation Development
Regulatory Support
6.6. Global mRNA Therapeutics CDMO Market, Sub-Segmentation Of Manufacturing Services, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Plasmid DNA Manufacturing
mRNA Synthesis
Lipid Nanoparticle (LNP) Formulation
Fill-Finish Services
6.7. Global mRNA Therapeutics CDMO Market, Sub-Segmentation Of Laboratory Services, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Quality Control Testing
Stability Testing
Bioanalytical Testing
Preclinical Testing
7. mRNA Therapeutics CDMO Market Regional And Country Analysis
7.1. Global mRNA Therapeutics CDMO Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global mRNA Therapeutics CDMO Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
